The analysis of demographic data from COVID19 patients who developed Ab (80.0%; n=125) and those without any immune response, showed the mean age (63.7 vs 71.4 years), was the sole statistically significant difference (P<.03; Table2). 100% (95% confidence interval [CI] = 96.3100.0; positive predictive value = 100%). By the 18th day from the onset of symptoms, we reached an optimal diagnostic sensitivity (more than 95.0%) In fact, the diagnostic sensitivity increased over time and between 15 and 25 days after symptoms onset, reached 95.5% (95% CI = 84.999.2). The new automated CLIA analyzer appeared to be a strong and reliable method to measure specific Ab against COVID19 at high throughput. Our data suggest that combining Ab and nucleic acid detection could increase diagnostic sensitivity. Keywords:COVID19, Euroimmun, immunoassay, MAGLUMI, SARSCoV2, serology Tivozanib (AV-951) == Highlights == In this manuscipt we showed, measuring Antibodies (Abdominal muscles) against COVID19 can increase the sensitivity of the detection of infected population. Clinically false negative results could be expected in the early stages of contamination, but clinically false positive results appeared to be rare. The age and early deaths were negatively related to Ab development. However, the time from symptoms onset to sampling, and to Tivozanib (AV-951) hospital admission, were positively related to Ab development. The CLIA method appeared to be reliable to measure Abs against COVID19 at a high throughput. == 1. INTRODUCTION == Since December 2019 we have been around the battlefield with a new threat to humanity, known as severe acute respiratory syndrome coronavirus 2 (SARSCoV2), which causes the coronavirus disease 2019 (COVID19), characterized by bilateral viral pneumonia. It may be asymptomatic or cause a variety of symptoms, ranging from anosmia and dysgeusia to acute respiratory distress syndrome and eventually death. There is no specific treatment and by 27 April 2020, SARSCoV2 has infected and killed more than 2 805 000 and 194 000 patients, respectively. These figures seem optimistic as we cannot yet detect all infected patients by the quantitative reverse transcriptasepolymerase chain reaction (RTqPCR).1 At present, the only reliable test for SARSCoV2 detection and COVID19 diagnosis is the RTqPCR, which is an expensive, timeconsuming, and laborious method to implement and requires some expertize and proficient clinical laboratories to perform the assay. Multiple factors such as suboptimal sampling, lower viral charges, sampling medium, and contamination could bias test results. One other way is usually to assess the immune response against SARSCoV22by the automated analyzer, which is usually faster, less expensive, random access, Tivozanib (AV-951) and could be considered as a complementary diagnostic tool in suspected patients with a negative RTqPCR result. Measuring specific antibodies (Abdominal muscles), therefore, will increase the sensitivity of the detection of the infected population. It also could be useful to assess how the human immune system responds over time. Hereby, we statement the performances of a fully automated chemiluminescent immunoassay (CLIA). == 2. MATERIALS AND METHODS == == 2.1. COVID19 positive subjects (COVID19 patients) == A total of 176 serum samples (samples) from 125 with confirmed COVID19 (COVID19 patients) were randomly collected into serumgel tubes from 25 February to 10 Tivozanib (AV-951) March 2020. The inclusion criteria were symptomatic and hospitalized patients with positive RTqPCR assessments on nasopharyngeal swab samples and characteristic radiological lung patterns such as groundglass opacity and/or bilateral involvement. There were not any exclusion criteria besides the age (only patients 18 years old were included). Immunocompromised patients were not excluded from the study as we sought to know how their immune system will set in against COVID19. Among 125 selected COVID19 patients, we longitudinally followed 45 patients (2 samples) up to 25 days after the onset of symptoms to observe Ab development. All data included demographic, clinical, radiographic, and laboratory findings and time between symptoms onset and hospital admission, or full recovery or eventual death were obtained from patients’ medical records. The two first authors checked Rabbit polyclonal to BMPR2 all medical records at least three times until 27 April.
